[Management of patients with chronic pain: emerging perspectives and current practices.] / La gestione del paziente con dolore cronico: prospettive emergenti e pratiche attuali.

According to the International association for the study of pain (Aisd), chronic pain is «an unpleasant sensory and emotional experience associated with, or resembling, ongoing, or potential tissue damage¼. The evolution of the definition of chronic pain has recognized the centrality of subjective and multidimensional valence, involving biological, psychological, and social aspects. Hence, there is a need to introduce patient-centered medicine and broaden the chronic pain management modalities. The primary clinical goal purpose does not end with the biological dimension and treatment of pain but should include the patient's individual experience and maintain an interdisciplinary value, including pharmacological therapy, as well as psychological care and integrative interventions. The perspectives illustrated provided the theoretical rationale for the organization of the Pain Clinic at Asst Santi Paolo e Carlo University Hospitals in Milan. The articulation of this care pathway can serve as a model, which can be applied to other clinical settings, where an interdisciplinary and multimodal approach is needed.

Agranulocytosis and hepatic toxicity with ticlopidine therapy: a case report.

INTRODUCTION: Ticlopidine is a platelet inhibitor used to prevent thrombosis in patients with cerebrovascular or coronary artery disease. The most common side effects are mild and transitory: diarrhea, dyspepsia, nausea and rashes. More serious, but less frequent, adverse effects are hematological dyscrasia and cholestatic hepatitis. We report a rare case of agranulocytosis associated with hepatic toxicity, probably related to the use of ticlopidine. CASE PRESENTATION: A 70-year-old Caucasian woman, with no previous history of hematological or liver diseases, was treated with ticlopidine 250 mg twice daily immediately after a vertebrobasilar stroke. Upon admission, her blood tests were normal. About four weeks later she developed agranulocytosis and hepatic toxicity. Ticlopidine was discontinued immediately, and aspirin 25 mg and dipyridamole 200 mg were given twice daily. She was treated with hematopoietic growth factors (granulocyte colony stimulating factor), with a rapidly increased white blood count and progressive normalization of liver tests as a result. CONCLUSION: In the first three months following initiation of ticlopidine therapy, regular monitoring of complete blood cell count and of liver function tests is essential for the early detection of serious and unpredictable side effects.